These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7597072)

  • 1. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
    Cohen OJ; Pantaleo G; Holodniy M; Schnittman S; Niu M; Graziosi C; Pavlakis GN; Lalezari J; Bartlett JA; Steigbigel RT
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):6017-21. PubMed ID: 7597072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.
    Perrin L; Yerly S; Marchal F; Schockmel GA; Hirschel B; Fox CH; Pantaleo G
    J Infect Dis; 1998 Jun; 177(6):1497-501. PubMed ID: 9607825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
    Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
    AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E;
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
    Lafeuillade A; Poggi C; Profizi N; Tamalet C; Costes O
    J Infect Dis; 1996 Aug; 174(2):404-7. PubMed ID: 8699075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
    Mueller BU; Sei S; Anderson B; Luzuriaga K; Farley M; Venzon DJ; Tudor-Williams G; Schwartzentruber DJ; Fox C; Sullivan JL; Pizzo PA
    J Pediatr; 1996 Sep; 129(3):410-8. PubMed ID: 8804331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D; Bethel J; Wainberg MA; Weislow O; Schnittman S
    J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
    Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
    AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
    Wong JK; Günthard HF; Havlir DV; Zhang ZQ; Haase AT; Ignacio CC; Kwok S; Emini E; Richman DD
    Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12574-9. PubMed ID: 9356491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
    Günthard HF; Havlir DV; Fiscus S; Zhang ZQ; Eron J; Mellors J; Gulick R; Frost SD; Brown AJ; Schleif W; Valentine F; Jonas L; Meibohm A; Ignacio CC; Isaacs R; Gamagami R; Emini E; Haase A; Richman DD; Wong JK
    J Infect Dis; 2001 May; 183(9):1318-27. PubMed ID: 11294662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
    Yerly S; Kaiser L; Baumberger C; Hirschel B; Perrin LH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):358-64. PubMed ID: 7882100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds.
    Bagnarelli P; Menzo S; Valenza A; Paolucci S; Petroni S; Scalise G; Sampaolesi R; Manzin A; Varaldo PE; Clementi M
    J Clin Microbiol; 1995 Jan; 33(1):16-23. PubMed ID: 7699034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States.
    Harris M; Patenaude P; Cooperberg P; Filipenko D; Thorne A; Raboud J; Rae S; Dailey P; Chernoff D; Todd J; Conway B; Montaner JS
    J Infect Dis; 1997 Nov; 176(5):1388-92. PubMed ID: 9359745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies.
    Cohen OJ; Pantaleo G; Lam GK; Fauci AS
    Springer Semin Immunopathol; 1997; 18(3):305-22. PubMed ID: 9089951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.
    Stellbrink HJ; Hufert FT; Tenner-Racz K; Lauer J; Schneider C; Albrecht H; Racz P; van Lunzen J
    Antivir Ther; 1998; 3(4):209-14. PubMed ID: 10682140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.